SARTORIUS AG (SRT.DE) Stock Fundamental Analysis
Europe - FRA:SRT - DE0007165607 - Common Stock
183.2 EUR
-1.2 (-0.65%)
Taking everything into account, SRT scores 3 out of 10 in our fundamental rating. SRT was compared to 20 industry peers in the Life Sciences Tools & Services industry. SRT has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, SRT is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year SRT was profitable.
SRT had a positive operating cash flow in the past year.
In the past 5 years SRT has always been profitable.
Each year in the past 5 years SRT had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.04%, SRT is doing worse than 75.00% of the companies in the same industry.
SRT has a Return On Equity of 3.92%. This is in the lower half of the industry: SRT underperforms 75.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.80%, SRT is doing worse than 65.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for SRT is in line with the industry average of 7.27%.
The 3 year average ROIC (8.34%) for SRT is well above the current ROIC(3.80%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.04% | ||
| ROE | 3.92% | ||
| ROIC | 3.8% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
1.3 Margins
The Profit Margin of SRT (3.00%) is worse than 70.00% of its industry peers.
In the last couple of years the Profit Margin of SRT has declined.
The Operating Margin of SRT (12.48%) is worse than 60.00% of its industry peers.
SRT's Operating Margin has declined in the last couple of years.
SRT has a Gross Margin of 45.76%. This is in the better half of the industry: SRT outperforms 80.00% of its industry peers.
In the last couple of years the Gross Margin of SRT has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.48% | ||
| PM (TTM) | 3% | ||
| GM | 45.76% |
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so SRT is still creating some value.
SRT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SRT has more shares outstanding
The debt/assets ratio for SRT has been reduced compared to a year ago.
2.2 Solvency
SRT has an Altman-Z score of 2.02. This is not the best score and indicates that SRT is in the grey zone with still only limited risk for bankruptcy at the moment.
SRT has a worse Altman-Z score (2.02) than 60.00% of its industry peers.
The Debt to FCF ratio of SRT is 8.09, which is on the high side as it means it would take SRT, 8.09 years of fcf income to pay off all of its debts.
SRT has a Debt to FCF ratio of 8.09. This is in the lower half of the industry: SRT underperforms 65.00% of its industry peers.
A Debt/Equity ratio of 1.54 is on the high side and indicates that SRT has dependencies on debt financing.
With a Debt to Equity ratio value of 1.54, SRT is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.54 | ||
| Debt/FCF | 8.09 | ||
| Altman-Z | 2.02 |
ROIC/WACC0.51
WACC7.5%
2.3 Liquidity
A Current Ratio of 1.39 indicates that SRT should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.39, SRT is doing worse than 60.00% of the companies in the same industry.
SRT has a Quick Ratio of 1.39. This is a bad value and indicates that SRT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.88, SRT is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.39 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 33.21% over the past year.
SRT shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -11.87% yearly.
The Revenue has been growing slightly by 3.80% in the past year.
Measured over the past years, SRT shows a quite strong growth in Revenue. The Revenue has been growing by 13.10% on average per year.
EPS 1Y (TTM)33.21%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%7.02%
Revenue 1Y (TTM)3.8%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%2.74%
3.2 Future
SRT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.16% yearly.
The Revenue is expected to grow by 8.92% on average over the next years. This is quite good.
EPS Next Y23.27%
EPS Next 2Y20.61%
EPS Next 3Y22.38%
EPS Next 5Y19.16%
Revenue Next Year5.14%
Revenue Next 2Y7.17%
Revenue Next 3Y8.54%
Revenue Next 5Y8.92%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 42.11, the valuation of SRT can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of SRT indicates a slightly more expensive valuation: SRT is more expensive than 65.00% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.90. SRT is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 30.74 indicates a quite expensive valuation of SRT.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRT indicates a slightly more expensive valuation: SRT is more expensive than 65.00% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.36, SRT is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.11 | ||
| Fwd PE | 30.74 |
4.2 Price Multiples
SRT's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SRT indicates a somewhat cheap valuation: SRT is cheaper than 65.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.84 | ||
| EV/EBITDA | 20.53 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as SRT's earnings are expected to grow with 22.38% in the coming years.
PEG (NY)1.81
PEG (5Y)N/A
EPS Next 2Y20.61%
EPS Next 3Y22.38%
5. Dividend
5.1 Amount
SRT has a yearly dividend return of 0.41%, which is pretty low.
SRT's Dividend Yield is comparable with the industry average which is at 0.71.
With a Dividend Yield of 0.41, SRT pays less dividend than the S&P500 average, which is at 2.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.41% |
5.2 History
The dividend of SRT has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
48.70% of the earnings are spent on dividend by SRT. This is a bit on the high side, but may be sustainable.
The dividend of SRT is growing, but earnings are growing more, so the dividend growth is sustainable.
DP48.7%
EPS Next 2Y20.61%
EPS Next 3Y22.38%
FRA:SRT (10/7/2025, 2:55:06 PM)
183.2
-1.2 (-0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners4.37%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap13.72B
Analysts80
Price Target257.81 (40.73%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.41% |
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP48.7%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.33%
Min EPS beat(2)-10.52%
Max EPS beat(2)-4.13%
EPS beat(4)0
Avg EPS beat(4)-10.28%
Min EPS beat(4)-22.4%
Max EPS beat(4)-4.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.97%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)2.67%
Revenue beat(4)2
Avg Revenue beat(4)0.69%
Min Revenue beat(4)-4.07%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.34%
PT rev (3m)-11.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.25%
EPS NY rev (1m)0.59%
EPS NY rev (3m)0.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.15%
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)-1.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.11 | ||
| Fwd PE | 30.74 | ||
| P/S | 3.96 | ||
| P/FCF | 23.84 | ||
| P/OCF | 14.93 | ||
| P/B | 5.16 | ||
| P/tB | N/A | ||
| EV/EBITDA | 20.53 |
EPS(TTM)4.35
EY2.37%
EPS(NY)5.96
Fwd EY3.25%
FCF(TTM)7.68
FCFY4.19%
OCF(TTM)12.27
OCFY6.7%
SpS46.31
BVpS35.5
TBVpS-35.06
PEG (NY)1.81
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.04% | ||
| ROE | 3.92% | ||
| ROCE | 5.11% | ||
| ROIC | 3.8% | ||
| ROICexc | 4.21% | ||
| ROICexgc | 13.6% | ||
| OM | 12.48% | ||
| PM (TTM) | 3% | ||
| GM | 45.76% | ||
| FCFM | 16.59% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexcg growth 3Y-35.26%
ROICexcg growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.54 | ||
| Debt/FCF | 8.09 | ||
| Debt/EBITDA | 4.76 | ||
| Cap/Depr | 80.56% | ||
| Cap/Sales | 9.91% | ||
| Interest Coverage | 2.25 | ||
| Cash Conversion | 106.92% | ||
| Profit Quality | 552.64% | ||
| Current Ratio | 1.39 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 2.02 |
F-Score7
WACC7.5%
ROIC/WACC0.51
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)33.21%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%7.02%
EPS Next Y23.27%
EPS Next 2Y20.61%
EPS Next 3Y22.38%
EPS Next 5Y19.16%
Revenue 1Y (TTM)3.8%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%2.74%
Revenue Next Year5.14%
Revenue Next 2Y7.17%
Revenue Next 3Y8.54%
Revenue Next 5Y8.92%
EBIT growth 1Y1.03%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year99.69%
EBIT Next 3Y38.21%
EBIT Next 5Y26.49%
FCF growth 1Y187.94%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y14.51%
OCF growth 3Y4.07%
OCF growth 5Y20.79%